Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Millennium Management LLC

Millennium Management LLC increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 13.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,842,063 shares of the biotechnology company’s stock after purchasing an additional 218,518 shares during the quarter. Millennium Management LLC owned 3.35% of Astria Therapeutics worth $16,763,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ATXS. ADAR1 Capital Management LLC purchased a new stake in shares of Astria Therapeutics during the fourth quarter valued at $1,469,000. Perceptive Advisors LLC lifted its stake in Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after buying an additional 1,814,608 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 2,861 shares during the period. Finally, American International Group Inc. raised its holdings in shares of Astria Therapeutics by 49.4% during the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after acquiring an additional 8,122 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ATXS has been the subject of several recent analyst reports. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. TD Cowen initiated coverage on Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Oppenheimer boosted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, September 27th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $25.20.

Astria Therapeutics Price Performance

ATXS opened at $11.87 on Friday. The company has a market capitalization of $651.82 million, a PE ratio of -5.12 and a beta of 0.71. Astria Therapeutics, Inc. has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The business has a 50-day moving average of $11.30 and a 200-day moving average of $10.73.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, equities research analysts expect that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current fiscal year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.